FGF21 and type 2 diabetes mellitus: A subgroup analysis of a Phase 3 trial involving patients with type 2 diabetes mellitus and hypertriglyceridemia revealed that pemafibrate decreased the HOMA‐IR level and improved insulin resistance through an increase in the serum fibroblast growth factor 21 level.31